Report topline data from pivotal arimoclomol studies in ALS and IBM
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 2 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- May 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Topline data read-outs from pivotal studies of arimoclomol in ALS and IBM in H1 2021”
What we found
Evidence strength A What the grades mean
Topline results for both pivotal trials were announced within H1 2021: the IBM trial in March 2021 and the ALS trial in May 2021. Both results were negative.
-
A Orphazyme A/S 6-K filed 2021-08-31
“Topline data were presented at the virtual European Network to Cure ALS (ENCALS) meeting in May 2021” ✓ confirmed on the page
-
A Orphazyme A/S 6-K filed 2021-08-31
“In May 2021, Orphazyme announced that the Phase 3 ORARIALS-01 pivotal trial of arimoclomol in ALS did not meet its primary and secondary endpoints.” ✓ confirmed on the page
-
A Orphazyme A/S 20-F filed 2022-06-28
“In March 2021, we announced that our Phase 2/3 trial in IBM did not meet its primary and secondary endpoints, and in May 2021 we announced that our Phase 3 trial in ALS did not meet its primary and secondary endpoints.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Topline data from pivotal arimoclomol studies in ALS and IBM
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Orphazyme A/S? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C764791-024993 · Corrections policy